We have had a timely reminder from Sareum that there is more to the company than its lead CHK1 inhibitor candidate which is currently undergoing two phase 1 clinical trials. The specialist cancer drug discovery and development business has announced that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with Sareum's Aurora+FLT3 Kinase Inhibitor Programme. These patents describe compounds that inhibit
08 Aug 2016
Further patents on Aurora/FLT3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further patents on Aurora/FLT3
Sareum Holdings plc (SAR:LON) | 31.5 -0.6 (-6.0%) | Mkt Cap: 32.0m
- Published:
08 Aug 2016 -
Author:
Derren Nathan -
Pages:
6
We have had a timely reminder from Sareum that there is more to the company than its lead CHK1 inhibitor candidate which is currently undergoing two phase 1 clinical trials. The specialist cancer drug discovery and development business has announced that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with Sareum's Aurora+FLT3 Kinase Inhibitor Programme. These patents describe compounds that inhibit